Ranbaxy, Cadila Healthcare, Aurobindo Pharma, Divi's Labs, Wockhardt

 Ranbaxy, Cadila Healthcare, Aurobindo Pharma, Divi's Labs, Wockhardt

Divis Laboratories

Divis Laboratories

Larsen and Tourbo, Divi's Labs, Mahindra and Mahindra, Sesa Goa

Larsen and Tourbo, Divi's Labs, Mahindra and Mahindra, Sesa Goa

ITC, Divis Labs, India Energy, India Banking, India Automobiles

ITC, Divis Labs, India Energy, India Banking, India Automobiles

Divis Labs

Divis Labs

Divi's Labs

Divi's Labs

Cipla, Divi's Laboratories, Nagarjuna Construction

Cipla, Divi's Laboratories, Nagarjuna Construction

Bharti Airtel, Cipla, Cummins, Divi's Labs, GVK Power and Infrastructure, IDFC

Bharti Airtel, Cipla, Cummins, Divi's Labs, GVK Power and Infrastructure, IDFC

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Investors with a long-term perspective can consider accumulating the stock of Divi's Laboratories, an established player in the global pharmaceutical outsourcing market. Divi has well-established working relationships with a number of the top 20 global innovator firms. With global pharma companies beginning to restock inventories, it will only be a matter of time before it reflects in the company's financial performance.

Britannia Industries, Divi's Labs, Godrej Properties, ILFs, India Strategy, Unichem, Sesa Goa

Britannia Industries, Divi's Labs, Godrej Properties, ILFs, India Strategy, Unichem, Sesa Goa

Divi's Labs, Essar Shipping, Greaves Cotton, Cummins, AIA Engineering, Indraprastha Gas, SBI, GDL, Great Offshore

Divi's Labs, Essar Shipping, Greaves Cotton, Cummins, AIA Engineering, Indraprastha Gas, SBI, GDL, Great Offshore

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

Divi's Labs

ONGC, Cairn India, Mahindra and Mahindra, Sun TV, Divi's Labs, Aban Offshore, CESC, Sobha Developers, Unitech

ONGC, Cairn India, Mahindra and Mahindra, Sun TV, Divi's Labs, Aban Offshore, CESC, Sobha Developers, Unitech

Your Ad Here

ONGC, Sun TV, Larsen and Tourbo, Sterlite Industries, Hindalco, Divis, BPCL, Educomp Solutions, Tata Tea, Mphasis, Phoenix Mills

ONGC, Sun TV, Larsen and Tourbo, Sterlite Industries, Hindalco, Divis, BPCL, Educomp Solutions, Tata Tea, Mphasis, Phoenix Mills, Mahindra Lifespace Developers, Dish TV, Bharat Electronics, Aban Offshore, HDFC Bank

Divi's Laboratories

Investments with a two-three year perspective can be considered in the stock of Divi’s Laboratories, a leading player in the pharma contract manufacturing space.

The growing size of its bulk drug business catering to both generic and custom synthesis clients, sustainable operating efficiencies (high EBITDA margins of 40 per cent) and presence of future growth drivers such as peptides and carotenoids point to good earnings prospects for Divi’s.

Divi’s clocked a robust performance driven by organic growth in the third quarter of 2007-08 (September-December) with 90 per cent increase in sales. Custom chemical synthesis vertical (where it provides custom-made compounds) witnessed over a 100 per cent growth, and the generics bulk drugs business clocked nearly a 60 per cent growth on a year-on-year basis. Given its solid performance, Divi’s may be expected to breach the Rs 1,000-crore sales mark for the full 12 months and sustain high operating margins and lower effective tax rate.

At the current market price of Rs 1,400, the stock trades at around 19 times its likely 2008-09 per share earnings. This appears reasonable given Divi’s historical earnings growth (five-year compounded annual profit growth rate of 24 per cent) and expected ramp-up in earnings in 2008-09 owing to additional earnings from the nutraceuticals venture.
Business scenario

At present, the revenues of Divi’s Laboratories are derived in equal parts from the generic bulk drug and custom chemical synthesis segments. Improved product mix in favour of the high-margin custom synthesis business, has translated into higher margins (from 32 per cent to 40 per cent) as the contribution from custom synthesis has grown to 50 per cent from less than 30 per cent in 2006.

Divi’s is engaged in developing processes and custom synthesis of several drug ingredients and intermediate compounds for multinational companies for their discovery products.

These are under various stages of clinical trials (over 60 compounds). As trials progress, volumes in the custom synthesis business tend to be scaled up, especially in the run up to the commercial launch of the molecule. It is to be noted that during 2006-07, the company spent Rs 240 crore on capital expenditure towards enhancing capacities as it set up new production and utility facilities in SEZ (near Vizag) and EOU units (Chippada village in AP).

The other major business segment relates to manufacturing off-patent bulk drugs and also those that are about to enter generic status shortly (catering to generic clients); this has also done well. Divi’s has over 30 drug master files and currently has over 60 products in its bulk drug portfolio. In July-August, a blockbuster epileptic drug will face generic competition and Divi’s is expected to partner the first-to-file generic company for supply of ingredients.
Broad-based products

At end-FY07, on a product basis, Divi’s largest product accounted for one-fifth of the sales, while the top five products contributed more than half of the revenues.

These ratios are expected to change in FY-08 as its product and customer basket widens. Furthermore, revenues from niche segments such as the peptides and carotenoids products manufactured by Divi’s would also gain market approval. Peptide drugs are one of the emerging areas of drug discovery (especially in cancer medicines) presenting significant opportunity as Western companies completely outsource the peptide segment and related derivatives to Asia. Divi’s currently has exposure to around 90 peptide building blocks.

Carotenoids, on the other hand, are pigments that are important in human nutrition as a source of vitamins and preventive agents for cancer and heart diseases. Divi’s two 100 per cent subsidiaries — Divi’s Laboratories (USA) Inc and Divi’s Laboratories Europe AG (Switzerland) are specifically constituted for marketing its nutraceuticals. Divi’s nutraceuticals project is housed at its Rs 102-crore SEZ. The nutraceuticals venture (with nine products spread across dietary supplement, health and personal care etc.) is expected to pay-off soon with key production facilities commissioned recently.
Risks

Divi’s operates predominantly in export markets and has substantial exposure to foreign exchange fluctuations. However, it has a natural hedge in the form of a import component of about 50 per cent in raw materials. Sales from contract manufacturing are linked to long-term contracts, which reduces flexibility in pricing.

There has been a significant reduction in the effective tax rate for Divi’s, due to time-bound tax-breaks availed by the company as commercialisation of its SEZ and EOU units have occurred; but old units may lose these benefits soon.